These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17891054)

  • 1. Recreational use of 3,4-methylenedioxymethamphetamine ('ecstasy') relieving symptoms of posterior scleritis.
    Witters JG; Kestelyn P; Van Slycken S; Verstraete A; Van Aken EH
    Eye (Lond); 2007 Dec; 21(12):1535-7. PubMed ID: 17891054
    [No Abstract]   [Full Text] [Related]  

  • 2. Hazards associated with the recreational drug 'ecstasy'.
    O'Connor B
    Br J Hosp Med; 1994 Nov 16-Dec 13; 52(10):507, 510-4. PubMed ID: 7858800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathology of the ring-substituted amphetamine analogue 3,4-methylenedioxymethylamphetamine (MDMA, 'Ecstasy').
    Rutty GN; Milroy CM
    J Pathol; 1997 Mar; 181(3):255-6. PubMed ID: 9155708
    [No Abstract]   [Full Text] [Related]  

  • 4. [Other factors that condition the long-term toxicity of 3,4 methylenedioxymethamphetamine ('ecstasy')].
    Abanades S; Cabrero-Castel A; Barral D; Alvarez Y; Farré M
    Rev Neurol; 2006 Apr 1-15; 42(7):447; author reply 447-8. PubMed ID: 16602067
    [No Abstract]   [Full Text] [Related]  

  • 5. Bruxism after 3,4-methylenedioxymethamphetamine (ecstasy) abuse.
    Dinis-Oliveira RJ; Caldas I; Carvalho F; Magalhães T
    Clin Toxicol (Phila); 2010 Oct; 48(8):863-4. PubMed ID: 20515398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine ('Ecstasy') abuse.
    Hanyu S; Ikeguchi K; Imai H; Imai N; Yoshida M
    Eur Neurol; 1995; 35(3):173. PubMed ID: 7628499
    [No Abstract]   [Full Text] [Related]  

  • 7. Recreational ecstasy use: acute effects potentiated by ambient conditions?
    Bedi G; Redman J
    Neuropsychobiology; 2006; 53(2):113; author reply 114. PubMed ID: 16557042
    [No Abstract]   [Full Text] [Related]  

  • 8. Bilateral angle-closure glaucoma after combined consumption of "ecstasy" and marijuana.
    Trittibach P; Frueh BE; Goldblum D
    Am J Emerg Med; 2005 Oct; 23(6):813-4. PubMed ID: 16182995
    [No Abstract]   [Full Text] [Related]  

  • 9. Ecstasy (MDMA) and oral health.
    Brand HS; Dun SN; Nieuw Amerongen AV
    Br Dent J; 2008 Jan; 204(2):77-81. PubMed ID: 18268544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fatal trip with ecstasy: a case of 3,4-methylenedioxymethamphetamine/3,4- methylenedioxyamphetamine toxicity.
    Coore JR
    J R Soc Med; 1996 Jan; 89(1):51P-2P. PubMed ID: 8709087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
    Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
    J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brain functional disorders after taking Ecstasy?].
    von Wilmsdorff M; Gastpar M
    Dtsch Med Wochenschr; 1995 Dec; 120(49):1716. PubMed ID: 7497899
    [No Abstract]   [Full Text] [Related]  

  • 13. Posterior scleritis mimicking macular serpiginous choroiditis.
    Sonika ; Narang S; Kochhar S; Srivastava M; Gupta R; Sood S
    Indian J Ophthalmol; 2003 Dec; 51(4):351-3. PubMed ID: 14750626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
    Fisk JE; Montgomery C; Murphy PN
    Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The agony of the ecstasy: serotonin and obstructive sleep apnea.
    Chamberlin NL; Saper CB
    Neurology; 2009 Dec; 73(23):1947-8. PubMed ID: 19955498
    [No Abstract]   [Full Text] [Related]  

  • 16. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K; Parrott A; Turner J
    J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morbidity and mortality caused by use of ecstasy].
    de Man RA
    Ned Tijdschr Geneeskd; 1994 Sep; 138(37):1850-5. PubMed ID: 7935920
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
    Meyer JS; Piper BJ; Vancollie VE
    Ann N Y Acad Sci; 2008 Oct; 1139():151-63. PubMed ID: 18991859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.